PlusCBD Oil™ Capsules featured as one of the industry-leading in efficacy and strength; Dr. Oz segment cites sales of CBD products expected to increase 700% over the next year
LAS VEGAS, Oct. 09, 2018 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), preeminent supplier and manufacturer of hemp-derived phytocannabinoids including industry leading brand, PlusCBD Oil™, today announced its feature on the Oct. 3rd episode of ‘The Dr. Oz Show.’
The segment showcased Dr. Oz and Dr. Sanjay Gupta, Chief Medical Correspondent for CNN, where both doctors agreed that CBD, “has legitimate medical benefits,” and also stated that the varying milligram levels of CBD in products created different end-user experiences.
“Our product appearance on The Dr. Oz Show further solidifies our position that independent analysis of PlusCBD Oil™ places us as an industry leader,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “The exposure from appearing on The Dr. Oz Show allows us to introduce our product to a whole new segment of customers. Our leadership role in setting the standard for transparency across all media outlets will continue to be a focus of our Company.”
Mr. Dowling continued, “The Dr. Oz Show also discussed the expanding market for CBD product sales which are expected to increase 700% over the next year. CV Sciences is capitalizing on this trend through increased operating scale, expansion of vertical markets and development of new products.”
To learn more and view clips of the segment, visit The Dr. Oz. Show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.